These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 38686671)

  • 1. Novel Isoalantolactone-Based Derivatives as Potent NLRP3 Inflammasome Inhibitors: Design, Synthesis, and Biological Characterization.
    Zhao M; Ye N; Liu L; Zhang RJ; Li N; Peng J; Cai XY; Jiang XQ; Su KY; Zhang XL; Rao QR; Liu KJ; Deng DX; Peng AH; Tang MH; Chen LJ; Wu WS; Ye HY
    J Med Chem; 2024 May; 67(9):7516-7538. PubMed ID: 38686671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of dronedarone and its analogues as NLRP3 inflammasome inhibitors with potent anti-inflammation activity.
    Chen H; Chen X; Sun P; Wu D; Yue H; Pan J; Li X; Zhang C; Wu X; Hua L; Hu W; Yang Z
    Bioorg Med Chem Lett; 2021 Aug; 46():128160. PubMed ID: 34062252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of Novel Pterostilbene-Based Derivatives as Potent and Orally Active NLRP3 Inflammasome Inhibitors with Inflammatory Activity for Colitis.
    Chen LZ; Zhang XX; Liu MM; Wu J; Ma D; Diao LZ; Li Q; Huang YS; Zhang R; Ruan BF; Liu XH
    J Med Chem; 2021 Sep; 64(18):13633-13657. PubMed ID: 34506712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of Novel Tetrahydroquinoline Inhibitors of NLRP3 Inflammasome for Potential Treatment of DSS-Induced Mouse Colitis.
    Dai Z; Chen XY; An LY; Li CC; Zhao N; Yang F; You ST; Hou CZ; Li K; Jiang C; You QD; Di B; Xu LL
    J Med Chem; 2021 Jan; 64(1):871-889. PubMed ID: 33332136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of pterostilbene analogs as novel NLRP3 inflammasome inhibitors for potential treatment of DSS-induced colitis in mice.
    Ruan B; Rong M; Ming Z; Wang K; Liu X; Deng L; Zhang X; Xu K; Shi C; Gao T; Liu X; Chen L
    Bioorg Chem; 2023 Apr; 133():106429. PubMed ID: 36841048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of Triazinone Derivatives as Novel, Specific, and Direct NLRP3 Inflammasome Inhibitors for the Treatment of DSS-Induced Ulcerative Colitis.
    Li N; Jiang X; Zhang R; Ye N; Tang M; Cai X; Su K; Peng J; Zhang X; Zhao M; Wu W; Ye H
    J Med Chem; 2023 Oct; 66(19):13428-13451. PubMed ID: 37756547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of 4-((E)-3,5-dimethoxy-2-((E)-2-nitrovinyl)styryl)aniline derivatives as potent and orally active NLRP3 inflammasome inhibitors for colitis.
    Zhang XX; Diao LZ; Chen LZ; Ma D; Wang YM; Jiang H; Ruan BF; Liu XH
    Eur J Med Chem; 2022 Jun; 236():114357. PubMed ID: 35428012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and biological evaluation of parthenolide derivatives with reduced toxicity as potential inhibitors of the NLRP3 inflammasome.
    Ou Y; Sun P; Wu N; Chen H; Wu D; Hu W; Yang Z
    Bioorg Med Chem Lett; 2020 Sep; 30(17):127399. PubMed ID: 32738997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heat shock transcription factor 2 reduces the secretion of IL-1β by inhibiting NLRP3 inflammasome activation in ulcerative colitis.
    Zhang F; Zhao W; Zhou J; Wang W; Luo J; Feng Y; Wu J; Li M; Wang K; Niu J; Miao Y
    Gene; 2021 Feb; 768():145299. PubMed ID: 33181254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 3-(2-Oxo-2-phenylethylidene)-2,3,6,7-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4(11bH)-one (compound 1), a novel potent Nrf2/ARE inducer, protects against DSS-induced colitis via inhibiting NLRP3 inflammasome.
    Wang Y; Wang H; Qian C; Tang J; Zhou W; Liu X; You Q; Hu R
    Biochem Pharmacol; 2016 Feb; 101():71-86. PubMed ID: 26588861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth differentiation factor 11 ameliorates experimental colitis by inhibiting NLRP3 inflammasome activation.
    Wang L; Wang Y; Wang Z; Qi Y; Zong B; Liu M; Li X; Zhang X; Liu C; Cao R; Ma Y
    Am J Physiol Gastrointest Liver Physiol; 2018 Dec; 315(6):G909-G920. PubMed ID: 30188752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The E3 Ubiquitin Ligase TRIM65 Negatively Regulates Inflammasome Activation Through Promoting Ubiquitination of NLRP3.
    Tang T; Li P; Zhou X; Wang R; Fan X; Yang M; Qi K
    Front Immunol; 2021; 12():741839. PubMed ID: 34512673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brevilin A inhibits NLRP3 inflammasome activation in vivo and in vitro by acting on the upstream of NLRP3-induced ASC oligomerization.
    Qin Q; Xu G; Zhan X; Wang Z; Wang Y; Liu H; Hou X; Shi W; Ma J; Bai Z; Xiao X
    Mol Immunol; 2021 Jul; 135():116-126. PubMed ID: 33892379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis and biological evaluation of tanshinone IIA derivatives as NLRP3 inflammasome inhibitors.
    Chen H; Yue H; Yan Y; Wu N; Wu D; Sun P; Hu W; Yang Z
    Bioorg Med Chem Lett; 2024 May; 104():129725. PubMed ID: 38555073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of chalcone analogues as novel NLRP3 inflammasome inhibitors with potent anti-inflammation activities.
    Zhang C; Yue H; Sun P; Hua L; Liang S; Ou Y; Wu D; Wu X; Chen H; Hao Y; Hu W; Yang Z
    Eur J Med Chem; 2021 Jul; 219():113417. PubMed ID: 33845232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 1'-Acetoxychavicol acetate inhibits NLRP3-dependent inflammasome activation via mitochondrial ROS suppression.
    Sok SPM; Ori D; Wada A; Okude H; Kawasaki T; Momota M; Nagoor NH; Kawai T
    Int Immunol; 2021 Jun; 33(7):373-386. PubMed ID: 33830232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ginsenoside Rd ameliorates colitis by inducing p62-driven mitophagy-mediated NLRP3 inflammasome inactivation in mice.
    Liu C; Wang J; Yang Y; Liu X; Zhu Y; Zou J; Peng S; Le TH; Chen Y; Zhao S; He B; Mi Q; Zhang X; Du Q
    Biochem Pharmacol; 2018 Sep; 155():366-379. PubMed ID: 30012462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oroxindin inhibits macrophage NLRP3 inflammasome activation in DSS-induced ulcerative colitis in mice via suppressing TXNIP-dependent NF-κB pathway.
    Liu Q; Zuo R; Wang K; Nong FF; Fu YJ; Huang SW; Pan ZF; Zhang Y; Luo X; Deng XL; Zhang XX; Zhou L; Chen Y
    Acta Pharmacol Sin; 2020 Jun; 41(6):771-781. PubMed ID: 31937929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of a novel and potent inhibitor with differential species-specific effects against NLRP3 and AIM2 inflammasome-dependent pyroptosis.
    Jiao Y; Nan J; Mu B; Zhang Y; Zhou N; Yang S; Zhang S; Lin W; Wang F; Xia A; Cao Z; Chen P; Pan Z; Lin G; Pan S; Bin H; Li L; Yang S
    Eur J Med Chem; 2022 Mar; 232():114194. PubMed ID: 35183871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Britannin as a novel NLRP3 inhibitor, suppresses inflammasome activation in macrophages and alleviates NLRP3-related diseases in mice.
    Shao JJ; Li WF; Sun JF; Zhuang ZS; Min JL; Long XH; Wu GJ; Xu HW; Liang G
    Acta Pharmacol Sin; 2024 Apr; 45(4):803-814. PubMed ID: 38172305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.